Open-label, Single-dose, Randomized, Two-way (Two-period) Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80mg) Administered Intravenously in Subjects With Chronic Heart Failure
Phase of Trial: Phase II/III
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Furosemide (Primary) ; Furosemide
- Indications Chronic heart failure
- Focus Pharmacokinetics; Registrational
- Sponsors scPharmaceuticals
- 20 Sep 2016 According to a scPharmaceuticals media release, data from this study were presented at the 20th Annual Heart Failure Society of America (HFSA) Scientific Meeting 2016.
- 20 Sep 2016 Results published in a scPharmaceuticals media release.
- 04 Nov 2015 Positive results published in scPharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History